ReviewFrontiers in bioengineering and biotechnology2025
Responsible AI in biotechnology: balancing discovery, innovation and biosecurity risks.
Review in Frontiers in bioengineering and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Artificial intelligence and automation in enzyme engineering: evolution, advances, and future perspectives.Bioresources and bioprocessing · 2026Review
- Artificial intelligence driven protein design and sustainable nanomedicine for advanced theranostics.Bioactive materials · 2026Review
- Precision Editing of NLRS Improves Effector Recognition for Enhanced Disease Resistance.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Self-driving bioprinting laboratories.Biofabrication · 2026Review
- Improving governance in the age of synthetic biology, artificial intelligence, and diverging threats.Frontiers in bioengineering and biotechnology · 2026Article
- Protein design, generative AI and biological security.Frontiers in microbiology · 2026Review
- Governing synthetic biology and artificial intelligence (AI) convergence: emerging biosecurity priorities for Africa.Frontiers in bioengineering and biotechnology · 2026Review
- Review
- CRISPR and Artificial Intelligence in Neuroregeneration: Closed-Loop Strategies for Precision Medicine, Spinal Cord Repair, and Adaptive Neuro-Oncology.International journal of molecular sciences · 2025Review
- Sequence-Based Protein-Protein Interaction Prediction and Its Applications in Drug Discovery.Cells · 2025Review
- Predicting pathogen evolution and immune evasion in the age of artificial intelligence.Computational and structural biotechnology journal · 2025Review
- Emerging technologies transforming the future of global biosecurity.Frontiers in digital health · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The integration of artificial intelligence (AI) in protein design presents unparalleled opportunities for innovation in bioengineering and biotechnology. However, it also raises significant biosecurity concerns. This review examines the changing landscape of bioweapon risks, the dual-use potential of AI-driven bioengineering tools, and the necessary safeguards to prevent misuse while fostering innovation. It highlights emerging policy frameworks, technical safeguards, and community responses aimed at mitigating risks and enabling responsible development and application of AI in protein design.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.